Texas Permanent School Fund Corp Boosts Stake in Corcept Therapeutics Incorporated
August 8, 2023
☀️Trending News
The Texas Permanent School Fund Corp has recently increased its stake in Corcept Therapeutics ($NASDAQ:CORT) Incorporated, according to an announcement from Defense World. Corcept Therapeutics Incorporated is a pharmaceutical company dedicated to discovering, developing and commercializing medicines for the treatment of severe metabolic and psychiatric disorders. The company focuses on the development of drugs targeting the glucocorticoid receptors, as well as several other therapeutic areas. Corcept Therapeutics Incorporated is currently involved in several clinical-stage product candidates that are either under development or in clinical trials. The company’s lead product candidate, Korlym, is a cortisol-inhibiting glucocorticoid modulator that has been approved by the US Food and Drug Administration (FDA) for the treatment of Cushing’s Syndrome in adults.
In addition, the company is currently developing Relacorilant, which is a next-generation selective glucocorticoid receptor modulator, as well as several other product candidates. The announcement is also likely to attract new investors to the company who are looking for a potentially profitable investment opportunity.
Market Price
On Monday, CORCEPT THERAPEUTICS Incorporated saw its stock surge by 0.5% to close at $25.5, up from its previous closing price of $25.4. The company is focused on developing treatments for serious mental and metabolic disorders. This investment comes at a time when CORCEPT THERAPEUTICS is preparing to launch a new drug, relacorilant, for the treatment of Cushing’s Syndrome. The company has stated that the new drug has the potential to be a double-digit blockbuster, meaning it could bring in billions of dollars in revenue.
This has undoubtedly attracted more investors to the company and certainly contributed to the increase in its stock price. Overall, this news indicates that CORCEPT THERAPEUTICS is doing well and that investors are bullish on its future prospects. As the company continues to develop treatments for serious mental and metabolic disorders, its stock is likely to remain stable and may even rise further as it launches more products. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Corcept Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 428.15 | 94.27 | 22.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Corcept Therapeutics. More…
| Operations | Investing | Financing |
| 135.28 | 161.35 | -159.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Corcept Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 524.62 | 103.01 | 4.15 |
Key Ratios Snapshot
Some of the financial key ratios for Corcept Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.8% | -11.2% | 23.1% |
| FCF Margin | ROE | ROA |
| 31.5% | 13.0% | 11.8% |
Analysis
GoodWhale has conducted an analysis of CORCEPT THERAPEUTICS‘s fundamentals. Our Star Chart reveals that CORCEPT THERAPEUTICS is strong in assets, growth, and profitability, but weak in dividend. The company also has a high health score of 10/10, indicating that its cashflows and debt are sound and that it is capable of riding out any crises without risk of bankruptcy. Based on these metrics, we have classified CORCEPT THERAPEUTICS as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Investors interested in such a company could benefit from the opportunity for long-term appreciation, as well as the potential for stable returns due to CORCEPT THERAPEUTICS’s sound financial profile. In addition, given CORCEPT THERAPEUTICS’s focus on healthcare, investors may be looking to benefit from the increasing demand for healthcare services in the long run. More…
Peers
The company’s competitors include RespireRx Pharmaceuticals Inc, Karyopharm Therapeutics Inc, and Shanghai Allist Pharmaceuticals Co Ltd.
– RespireRx Pharmaceuticals Inc ($OTCPK:RSPI)
The company’s market cap is 717.57k as of 2022 and its ROE is 10.74%. The company is a pharmaceutical company that focus on the development and commercialization of treatments for patients with respiratory diseases.
– Karyopharm Therapeutics Inc ($NASDAQ:KPTI)
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company that specializes in the development of drugs for the treatment of cancer and other diseases. The company has a market capitalization of 363.12 million as of 2022 and a return on equity of 46.62%. The company’s products are currently in clinical trials for the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 10.39B as of 2022. The company’s Return on Equity is 2.58%. Shanghai Allist Pharmaceuticals Co Ltd manufactures and sells pharmaceutical products in China. The company offers Western medicine, Chinese traditional medicine, health products, and medical devices. It also provides medical services.
Summary
Texas Permanent School Fund Corp recently increased their stock position in Corcept Therapeutics Incorporated, indicating positive sentiments around potential returns for investors. From an investing analysis perspective, Corecpt Therapeutics is an attractive option due to its strong financials and positive outlook. The company has a high current ratio, low debt, and growing revenue.
Additionally, its market capitalization is growing, indicating that the company’s shares are being increasingly valued by investors. Corcept Therapeutics also has a solid history of returns with its share price having surpassed analyst expectations in recent years. Therefore, Corcept Therapeutics looks to be a solid investment option for investors looking for long-term returns.
Related Posts
Recent Posts
